Tuesday, May 10, 2011
Inhibitex Inc., of Atlanta, said partner Pfizer Inc. presented Phase I data showing SA3Ag, a three-antigen Staphylococcus aureus vaccine, elicited a positive immune response to each of the three components.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.